1 / 19

The Role of the RAC in the Peer Review of CVM’s Risk Assessments

The Role of the RAC in the Peer Review of CVM’s Risk Assessments. Barry Hooberman, Ph.D., MPH Center for Veterinary Medicine Office of New Animal Drug Evaluation Rockville, MD 20855 September 30, 2003. Risk Assessments at CVM. Antimicrobial Resistance Human Food Safety Drug Residues

galia
Télécharger la présentation

The Role of the RAC in the Peer Review of CVM’s Risk Assessments

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Role of the RAC in the Peer Review of CVM’s Risk Assessments Barry Hooberman, Ph.D., MPH Center for Veterinary Medicine Office of New Animal Drug Evaluation Rockville, MD 20855 September 30, 2003

  2. Risk Assessments at CVM • Antimicrobial Resistance • Human Food Safety • Drug Residues • Animal Feeds • BSE • Contaminants (e.g., Dioxin)

  3. CVM’s Needs for Peer Review • Common to all Risk Assessments • Independent Review • Reviewers relationship with Agency • Access to sufficient data/information • Assess scientific reliability of data • Transparency/Openness • Much in common with CFSAN and FSIS

  4. CVM’s Needs for Peer Review • Distinct from CFSAN and FSIS • Organization • Size • Structure • Mission • New Drug Approvals • Past Drug Approvals • Subject Matter • Antimicrobial Resistance Risk Assessment (ARRA) vs. Microbial Risk Assessment (MRA)

  5. Organization of RA Activities • CFSAN: • CVM: • Risk Analysis Team • In the process of defining the boundaries between the assessors, managers, and communicators

  6. Risk Assessments and CVM’s Mission • New drug approvals • Guidance 152 • Review of past drug approvals • Confidentiality restrictions may limit external peer review • ARRA rely on publicly available information

  7. ARRA: Different from Microbial Risk Assessment • Microbial and Antimicrobial Resistance Risk Assessments for food safety overlap extensively in terms of • Microbiological properties of the hazard • Exposure pathways – follow the movement of bacteria in the food chain • Consequences – e.g., human infections • Key differences: • The hazardous agents are resistance determinants • Exposure – follow the movement of resistance determinants • Two separate pathways – direct and indirect • Consequences - generally requires a human intervention to translate into adverse health risks.

  8. Effects on RA Peer Review • Relatively limited resources • Efficient Allocation of resources for RA review • Regulatory considerations • Use and availability of data for external review • Use of risk assessment in the Center • Different complexity of risk problem • Less publicly available information on risk models

  9. Options for Peer Review • Internal review • Not independent • Sufficient access to data • Skills available to assess scientific reliability • Not transparent

  10. Options for Peer Review • Inter-Agency review • The Interagency Risk Assessment Consortium (RAC) • Semi-independent • Potential for sufficient access to data/information • Able to assess scientific reliability • Not transparent, but has potential for transparency (Food Risk Clearinghouse)

  11. Options for Peer Review • Public Meetings/Drafts of RA • Independent • Sufficient access to data/information • Range of skills in assessing scientific reliability of data • Transparent

  12. Options for Peer Review • Outside Experts • Range of independence • Used in planning, execution, and review of RAs • Used solely for review • Sufficient access to data/information • Able to assess scientific reliability of data • Range of transparency

  13. Options for Peer Review • Other • The Courts • Independent • Sufficient access to data/information • Varying skills to assess scientific reliability of data • Transparent • The problem of dueling experts! • Resource intensive

  14. CVM’s Experiences with Peer Review • Internal Review • Limited capabilities • Inter-Agency Review • RAC a very useful tool in the planning and execution of RAs • RAC participation in CVM Public Meetings • RAC project: Practice of Microbiological Risk Assessment by U.S. Government Agencies • EPA/OW funded • Incorporates Agency experience that will be useful to RA peer reviewers of future microbial risk assessments

  15. CVM’s Experiences with Peer Review • Public Meetings/Drafts • Extensively used • Wide range of comments on all aspects of risk assessment and beyond • Consultants/Outside experts • Consultants/Outside experts • Used in all phases in risk assessments • Resource-driven • Provide independent viewpoint

  16. CVM’s Experiences with Peer Review • Lessons Learned • Peer review is an important process that should be ongoing throughout the risk assessment • A contentious risk assessment is independent of good peer review procedures

  17. Observations/Questions • Resource allocation • The consumption of peer review resources is inversely proportional to the level of risk (chasing zero risk). • If the risk assessment finds the risk is from zero to very-nearly-zero, should we limit/control/attenuate scarce risk management resources on extensive peer reviews? • The consumption of peer review resources is proportional to the uncertainty in the estimate of risk • A highly uncertain, high risk estimate report consumes fewer peer review resources than an equivalently uncertain low risk estimate report • If contentiousness and length of reviews are driven by uncertainty, then these extremes in reported risk estimates should get the same level of peer review resources

  18. Observations/Questions • Boundaries for determining level of Peer Review • Based on magnitude (significance) of health effects, costs/benefits of risk management actions? • Use of outside experts in RA and peer review • Questions of independence • Relationship to Agency and regulated industry

  19. Acknowledgements • H. Gregg Claycamp • Mary Bartholomew

More Related